Bullish Case: Known: EDIT ~$3.04 is flat; front-dated options show extreme IV (puts ~500, calls traded more than puts) but very low volume—an event lottery. EDIT return-surface colors show a thin positive band amid heavier negative likelihood. A bullish rerate would likely follow Lyora-linked FDA/IND or licensing progress; SPY IV surface is comparatively smooth, so macro seems secondary. Prior catalyst bets missed; upside stays conditional (not base) into Aug expiries.

Bearish Case: Known: EDIT near $3 after the May sale; options keep pricing left-tail risk (OTM put IV in the hundreds). EDIT return-surface likelihood concentrates below 0% across holding windows (negative skew), with only a light positive tail. SPY IV surface shows no crisis-like re-pricing, pointing to company-specific dilution/illiquidity. With catalysts uncertain, downside drift is plausible into July 17/Aug 21 expiries. Earlier bearish downside-gap calls match skew; realized moves have been flatter.

Potential Outcomes:

1. 18% Catalyst: Lyora/partner PR or FDA acceptance for IND filings → rerate; falsifiable by press release/filing before Aug 22 with call IV compression.
2. 44% Drift: $2.7–$3.6 range; falsifiable by no incremental filings/financing news through Aug 21 and term IV staying contango.
3. 28% Dilution/-tail: ATM/secondary offering/S-3 → -15–-35%; falsifiable by announced equity raise or widened put skew.
4. 6% Liquidity stress/-60%: going-concern/financing failure.
5. 4% Takeover +50%+: 13D/strategic bid.

July 16, 2026